Expertise in
1
conditions

Peifen F. Fu

79 Qingchun Road, 
Hangzhou, CN 
Expertise in
1
conditions
79 Qingchun Road, 
Hangzhou, CN 
OverviewLocationsClinical Research

Overview

Peifen Fu practices in Hangzhou, China. Fu is highly rated in 1 condition, according to our data. Their top areas of expertise are Breast Cancer, Agranulocytosis, Epithelioid Sarcoma, Leukocytosis, and Mastectomy.

Their clinical research consists of co-authoring 74 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

79 Qingchun Road, Hangzhou, 310003, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Enrollment Status: Unknown
Publish Date: April 19, 2017
Intervention Type: Drug
Study Drugs: 5-Fu/Epirubicin/CTX Following Docetaxel, Docetaxel/Capecitabine Followed by Capecitabine/Epirubicin/Cyclophosphamide
Study Phase: Phase 3
View 1 Less Clinical Trial

74 Total Publications

Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study.
Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study.
Journal: BMC cancer
Published: February 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fu's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile